Jason M. Hafron, M.D., Partner and Director of Research, Michigan Institute of Urology, P.C.; Associate Professor of Urology, William Beaumont School of Medicine, Oakland University; Director of Robotic Surgery, William Beaumont Hospital, Royal Oak, Mich.
home / authors / jason-m-hafron-md-partner-and-director-research-michigan-institute-urology-pc-associate-professor
Articles
Upper tract transitional cell carcinoma: Diagnostic and therapeutic considerations
Raoul S. Concepcion, MD;Jason M. Hafron, M.D., Partner and Director of Research, Michigan Institute of Urology, P.C.; Associate Professor of Urology, William Beaumont School of Medicine, Oakland University; Director of Robotic Surgery, William Beaumont Hospital, Royal Oak, Mich.;Joelle Hamilton, MD;Jeremy D. Handel, MD
February 19th 2021Determining grade of disease is important, as nephron-sparing approaches may be feasible.
Latest Updated Articles
Published: December 23rd 2024 | Updated: January 23rd 2025
Bone Predominant mCRPC Patient Case
Published: May 7th 2024 | Updated: May 21st 2024
FDA accepts BLA for subcutaneous nivolumab in solid tumors
Published: April 17th 2025 | Updated: May 1st 2025
Urologists perform first remote robot–assisted HIFU for prostate cancer
Published: October 22nd 2021 | Updated: May 1st 2025
Collagenase clostridium histolyticum delivers incremental benefits across treatment cycles for Peyronie’s disease
Published: December 2nd 2021 | Updated: May 1st 2025
Dr. Eggener on why active surveillance should be “preferred” for low-risk prostate cancer
Published: December 6th 2021 | Updated: May 1st 2025
Adjuvant therapy for high-risk nonmetastatic RCC: Improving the treatment landscape
